分泌特异性抗体的杂交瘤细胞株、红细胞B抗体及应用
The preparation of erythrocyte B antibody using hybridoma technology solves the problem of stable mass production in existing technologies, and realizes the production of high-concentration, high-affinity erythrocyte B antibody, which is suitable for the accuracy and cost-effectiveness of blood typing methods.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- TIANJIN DEXIANG BIOTECHNOLOGY CO LTD
- Filing Date
- 2023-12-14
- Publication Date
- 2026-07-17
AI Technical Summary
Existing technologies make it difficult to produce stable, mass-produced erythrocyte B antibodies, which limits the development of blood typing methods in my country. Furthermore, commercial monoclonal antibodies rely on imports and are costly.
Hybridoma technology was used to immunize mouse spleen cells and mouse myeloma cells with membrane antigen B on erythrocyte membrane fragments to prepare hybridoma cell line C1. The resulting erythrocyte antibody B had high concentration and high affinity, and the antibody was purified by Protein A–Sephaorse 4B affinity chromatography.
Stable production of erythrocyte antibody B has been achieved, improving the accuracy and sensitivity of detection, reducing storage and transportation costs, and making it suitable for industrial applications.
Smart Images
Figure CN117701508B_ABST